维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

13篇 您的检索式：作者名="Brollo M"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Clinical,virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B显示文摘	Fattovich G Rugge M Brollo L Pontisso P Noventa F Guido M Alberti A Realdi G	1986	Hepatology1986，6，2：	1
	2	Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B显示文摘	Fattovich G Rugge M Brollo L	1986	Hepatology1986，6，2：	1
	3	Clinical,virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B显示文摘	Fattovich G Rugge M Brollo L	1986	Hepatology1986，16，6：	1
	4	Pharrnacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections显示文摘	Furlanut M Brollo L Lugatti E	2003	JAntimicrob Chemother2003，51，1：	1
	5	Pharmacokinetic aspects of levo-floxacin 500mg once daily during sequential intravenous/oral thera-py in patients with lower respiratory tract infections显示文摘	Furlanut M’Brollo L’Lugatti E	2003	J AntimicrobChemother2003，51，1：	1
	6	Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections显示文摘	Furlanut M Brollo L Lugatti E	2003	J Antimicrob Chemother2003，51，1：	1
	7	The New a-amino Acid N-hydroxy-nor-L-arginine : a High-affinity Inhibitor of Arginase Well Adapted to Bind to Its Manganese cluster 显示文摘	Custot J Moali C Brollo M	1997	J Am Chem Soc1997，119，17：	1
	8	Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti - HBe in chronic hepatitis type B 显示文摘	Fattovich G Rugge M Brollo L	1986	Hepatology1986，6，2：	1
	9	Pharmacokinetic aspects of Levofloxcin 500mg once daily during sequential intravenous/oral therapy inpatients with lower respiratory tract infections显示文摘	Furlant M Brollo L Lugatti E	2003	Antimicrob chemother2003，51，1：	1
	10	Pharmaeokinetie aspects of levofloxaein 500mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections显示文摘	Furlanut M Brollo L Lugatti E	2003	J Antimicrob Chemother2003，51，1：	1
	11	Pharmacokinetic aspects of levofloxa- cin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract ixffections显示文摘	Furlanut M Brollo L Lugatti E	2003	J Antimicrob Chemother2003，51，1：	1
	12	Pharmacokinetic aspects of Levofloxacin 500mg once daily during sequential intravenous/oral therapy inpatients with lower respiratory tract infections显示文摘	Furlanuf M Brollo L Lugatti E	2003	Antimicrob chemother2003，51，1：	1
	13	Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections显示文摘	FURLANNT M BROLLO L LUGATTI E	2003	J Antimicrob Chemother2003，51，1：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费